Posted On: 04/22/2015 1:53:55 PM
Post# of 145204
$DVAX at 2015 ASCO Annual Meeting
May 31
Lymphoma and Plasma Cell Disorders
Session Type: Poster Session
Track(s): Lymphoma and Plasma Cell Disorders
Presentation(s):
Abstract #TPS8604
Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas.
Michael Siavash Khodadoust, MD, PhD
Stanford University
ASCO requires strict confidentiality regarding the content of posters and abstracts presented, until about 2 weeks before the meeting. After the end of that "quiet period," we may get a $DVAX press release regarding the ASCO poster presentation of interim results of this study.
May 31
Lymphoma and Plasma Cell Disorders
Session Type: Poster Session
Track(s): Lymphoma and Plasma Cell Disorders
Presentation(s):
Abstract #TPS8604
Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas.
Michael Siavash Khodadoust, MD, PhD
Stanford University
ASCO requires strict confidentiality regarding the content of posters and abstracts presented, until about 2 weeks before the meeting. After the end of that "quiet period," we may get a $DVAX press release regarding the ASCO poster presentation of interim results of this study.
(0)
(0)
